Lexeo Therapeutics (LXEO) Change in Account Payables (2022 - 2026)

Lexeo Therapeutics (LXEO) has 5 years of Change in Account Payables data on file, last reported at -$1.6 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Account Payables fell 131.03% year-over-year to -$1.6 million; the trailing twelve-month figure through Mar 2026 stood at -$8.3 million (down 220.6% YoY), and the FY2025 full-year result was -$1.6 million, down 165.64% from the prior year.
• Change in Account Payables slipped to -$1.6 million in Q1 2026, from $200000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $8.4 million in Q2 2025 to a low of -$15.3 million in Q3 2025.
• A 5-year average of -$155714.3 and a median of $342000.0 in 2023 frame the typical range for Change in Account Payables.
• Across the five-year window, Change in Account Payables soared 838.62% in 2024 and tumbled 660.91% in 2025, its largest moves.
• Tracing LXEO's Change in Account Payables over 5 years: stood at -$1.2 million in 2022, then surged by 132.27% to $394000.0 in 2023, then tumbled by 618.27% to -$2.0 million in 2024, then jumped by 109.79% to $200000.0 in 2025, then slumped by 898.0% to -$1.6 million in 2026.
• Business Quant data shows LXEO's Change in Account Payables at -$1.6 million in Q1 2026, $200000.0 in Q4 2025, and -$15.3 million in Q3 2025.